New stock news | Yino Micro Medical Hong Kong IPO prospectus failed

Immvira Bioscience Inc. (referred to as Immvira Bioscience) submitted its Hong Kong IPO prospectus on June 25, which expired after 6 months on December 25, with Citigroup and CICC as its joint sponsors. According to the previous prospectus, Immvira Bioscience is a biotechnology company focusing on clinical demand-driven research. It is committed to discovering, developing, producing, and commercializing new oncolytic immunotherapy and engineered exosome therapy through proprietary bioengineering technology. The company designs a risk-sharing product portfolio, including oncolytic immunotherapy candidate drugs with the best potential for treating solid tumors and innovative engineered exosome therapy products with clinical application prospects or direct commercialization potential.